Evidence map›Paper›PMID 37510960›Full record

ArticleJournal of clinical medicine2023

Myeloid Sarcoma as a Presentation of Acute Myeloid Leukemia and Blastic Phase in the Course of Chronic Myeloid Leukemia: A Case Report and Literature Review.

Ugo Giordano, Mateusz Sawicki, Justyna Pilch, Jakub Mizera, Artur Borkowski, Krzysztof Zduniak, Jarosław Dybko

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ugo GiordanoDepartment of Nephrology and Transplant Medicine, University Clinical Hospital in Wroclaw, 50-556 Wrocław, Poland.ORCID 0009-0000-8735-3076
Mateusz SawickiLower Silesian Centre for Oncology, Pulmonology and Hematology in Wrocław, 53-439 Wroclaw, Poland.
Justyna PilchFaculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland.ORCID 0000-0001-8351-9622
Jakub MizeraFaculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland.ORCID 0000-0002-8112-9257
Artur BorkowskiDepartment of Nuclear Medicine and Endocrine Oncology, M. Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, 44-102 Gliwice, Poland.ORCID 0000-0002-1019-8976
Krzysztof ZduniakLower Silesian Centre for Oncology, Pulmonology and Hematology in Wrocław, 53-439 Wroclaw, Poland.
Jarosław DybkoLower Silesian Centre for Oncology, Pulmonology and Hematology in Wrocław, 53-439 Wroclaw, Poland.ORCID 0000-0003-3555-2887
Wroclaw Medical University · PLThe Maria Sklodowska-Curie National Research Institute of Oncology · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyeloid sarcoma (MS), also known as granulocytic sarcoma or chloroma, is a rare disease entity characterized by the emergence of an extramedullary tumor, which may be antecedent, coexisting, or manifest secondarily to an ongoing malignancy of lymphoid origin. Owing to its low prevalence, scientific reports addressing this matter comprise mainly retrospective studies with a limited number of participants, rather low-quality research, and only few case reports. Despite MS's rarity, the need for enhancing their diagnostic tools and refinement of their therapeutic regimens is broadly recognized among physicians. CASE SUMMARY: In this case series, we present the clinical histories of two patients diagnosed with MS. The former (Case 1) exhibited MS of the sternum alongside chronic myeloid leukemia (CML), while in case of the latter (Case 2) MS presented as the initial manifestation of a current acute myeloid leukemia (AML). Treatment for both patients included chemotherapy (CHTH) and radiation (RT); however, patient 1 with CML died due to cardiorespiratory insufficiency secondary to an infection, while patient 2 is in clinical remission (CR) for 16 months since their MS diagnosis. Furthermore, a comprehensive analysis of previously reported cases was conducted which incorporated MS in patients with AML and CML.

conclusionThe objective of this report was to emphasize the heterogeneity among the clinical manifestations of MS, to underline the relevance of the histopathological and molecular diagnostic tools in opting for the appropriate therapy, and that, in spite of it occurring rather uncommonly, physicians should think of MS in the presence of pathological masses in patients under risk of hematological malignancies.

Indexed as

acute myeloid leukemiacase reportchloromachronic myeloid leukemiagranulocytic sarcomamyeloid sarcoma

Identifiers

PMID37510960
PMCPMC10381590
OpenAlexW4385214573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.